Dr. Archana Barve, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3613 Nw 56th St, Suite 140, Okc, OK 73112 Phone: 405-949-6481 Fax: 405-795-5909 |
News Archive
ABC News: "Gangs across the country are arming themselves with powerful weapons to bilk taxpayers out of billions of dollars through Medicare fraud. What used to be a mostly non-violent, white collar crime has turned potentially deadly, and Federal agents who once combed through paperwork are now firing rounds at the shooting range to prepare for extreme dangers.
Shire plc has announced that it has signed an agreement with UCB to acquire the worldwide rights to EQUASYM IR and XL (methylphenidate hydrochloride) (excluding the USA, Canada and Barbados) used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Conditions related to obesity, including inflammation and leaky gut, leave the lungs of obese patients more susceptible to COVID-19 and may explain why they are more likely to die from the disease, UTSW scientists say in a new article published online in eLife.
In the current issue of Psychotherapy and Psychosomatics there are data about the long term-effects of a form of psychotherapy in depression compared to medication.
› Verified 4 days ago